10.57
+0.695(+7.04%)
Currency In USD
| Previous Close | 9.87 |
| Open | 9.91 |
| Day High | 10.71 |
| Day Low | 9.9 |
| 52-Week High | 16.19 |
| 52-Week Low | 6 |
| Volume | 23,293 |
| Average Volume | 33,347 |
| Market Cap | 34.33M |
| PE | -0.62 |
| EPS | -16.94 |
| Moving Average 50 Days | 10.19 |
| Moving Average 200 Days | 10.11 |
| Change | 0.7 |
If you invested $1000 in Surrozen, Inc. (SRZN) since IPO date, it would be worth $69.67 as of December 22, 2024 at a share price of $10.565. Whereas If you bought $1000 worth of Surrozen, Inc. (SRZN) shares 2 years ago, it would be worth $1,546.85 as of December 22, 2024 at a share price of $10.565.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Surrozen to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire Inc.
Nov 06, 2024 9:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, tod
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
GlobeNewswire Inc.
Nov 06, 2024 2:00 PM GMT
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 Nominated novel portfolio of preclinical ophthalmology product candidates to R&
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
GlobeNewswire Inc.
Nov 04, 2024 1:30 PM GMT
Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary FibrosisSOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -